VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
Recombinant Human Lactoferrin
Preclinical
Small molecule
J
Johns Hopkins University
1
Indications
2
Total Trials
0
Active Trials
0
Competitors
Pipeline
Status by Indication
[3]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Clostridium Difficile
Unknown status
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Clostridium Difficile
Preclinical
Unknown status
Clinical
Trials by Indication
[1]
Renal Cell Carcinoma
1 trial
Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell Carcinoma
Completed
·
A
Agennix
·
Phase 2
·
NCT00095186
·
40 enrolled
Clostridium Difficile
1 trial
Use of Recombinant Human Lactoferrin in Long-Term Care Patients With Feeding Tubes With Clostridium Difficile.
Unknown status
·
J
Johns Hopkins University
·
N/A
·
NCT00377078
·
30 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
2 trial records for Recombinant Human Lactoferrin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
Recombinant Human Lactoferrin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for Recombinant Human Lactoferrin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
Johns Hopkins University company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Small molecule
[2]
Highest Phase
Preclinical
[1]
Company
J
Johns Hopkins University
Related News